Display options
Cite
Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283doi: 10.3389/fimmu.2012.00283.
Astarita, J. L., Acton, S. E., & Turley, S. J. (2012). Podoplanin: emerging functions in development, the immune system, and cancer. Frontiers in immunology, 3283. https://doi.org/10.3389/fimmu.2012.00283
Astarita, Jillian L, et al. "Podoplanin: emerging functions in development, the immune system, and cancer." Frontiers in immunology vol. 3 (2012): 283. doi: https://doi.org/10.3389/fimmu.2012.00283
Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012 Sep 12;3:283. doi: 10.3389/fimmu.2012.00283. eCollection 2012. PMID: 22988448; PMCID: PMC3439854.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2012 Sep 12;3:283. doi: 10.3389/fimmu.2012.00283. eCollection 2012.

Podoplanin: emerging functions in development, the immune system, and cancer.

Frontiers in immunology

Jillian L Astarita, Sophie E Acton, Shannon J Turley

Affiliations

  1. Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute Boston, MA, USA ; Division of Medical Sciences, Harvard Medical School Boston, MA, USA.

PMID: 22988448 PMCID: PMC3439854 DOI: 10.3389/fimmu.2012.00283

Abstract

Podoplanin (PDPN) is a well-conserved, mucin-type transmembrane protein expressed in multiple tissues during ontogeny and in adult animals, including the brain, heart, kidney, lungs, osteoblasts, and lymphoid organs. Studies of PDPN-deficient mice have demonstrated that this molecule plays a critical role in development of the heart, lungs, and lymphatic system. PDPN is widely used as a marker for lymphatic endothelial cells and fibroblastic reticular cells of lymphoid organs and for lymphatics in the skin and tumor microenvironment. Much of the mechanistic insight into PDPN biology has been gleaned from studies of tumor cells; tumor cells often upregulate PDPN as they undergo epithelial-mesenchymal transition and this upregulation is correlated with increased motility and metastasis. The physiological role of PDPN that has been most studied is its ability to aggregate and activate CLEC-2-expressing platelets, as PDPN is the only known endogenous ligand for CLEC-2. However, more recent studies have revealed that PDPN also plays crucial roles in the biology of immune cells, including T cells and dendritic cells. This review will provide a comprehensive overview of the diverse roles of PDPN in development, immunology, and cancer.

Keywords: CLEC-2; cancer-associated fibroblasts; lymph node stromal cells; lymphatic endothelial cells; platelets; podoplanin

References

  1. Arch Pathol Lab Med. 2010 Oct;134(10):1520-7 - PubMed
  2. J Thromb Haemost. 2011 Jul;9 Suppl 1:44-55 - PubMed
  3. Science. 2003 Jan 10;299(5604):247-51 - PubMed
  4. Am J Clin Pathol. 2007 Nov;128(5):776-82 - PubMed
  5. J Exp Med. 2001 Dec 3;194(11):1649-60 - PubMed
  6. Eur J Immunol. 2001 Dec;31(12):3493-503 - PubMed
  7. J Immunol. 2004 Dec 15;173(12):7161-9 - PubMed
  8. Science. 2010 May 7;328(5979):749-52 - PubMed
  9. Rheumatology (Oxford). 2006 Jun;45(6):669-75 - PubMed
  10. Cell. 1995 Jun 2;81(5):695-704 - PubMed
  11. J Biol Chem. 2012 Jun 22;287(26):22241-52 - PubMed
  12. EMBO J. 2003 Jul 15;22(14):3546-56 - PubMed
  13. Neuro Oncol. 2012 Apr;14(4):426-39 - PubMed
  14. J Am Soc Nephrol. 2004 Mar;15(3):603-12 - PubMed
  15. Cancer Res. 2011 Jul 15;71(14):4769-79 - PubMed
  16. Mol Biol Cell. 2010 Dec;21(24):4387-99 - PubMed
  17. Int J Cancer. 2005 Mar 1;113(6):899-910 - PubMed
  18. Hum Pathol. 2005 Apr;36(4):372-80 - PubMed
  19. J Immunol. 2009 Dec 1;183(11):7169-77 - PubMed
  20. BMC Dev Biol. 2006 Jul 25;6:35 - PubMed
  21. Am J Physiol Lung Cell Mol Physiol. 2011 Jan;300(1):L32-42 - PubMed
  22. Nat Rev Cancer. 2009 Jan;9(1):40-55 - PubMed
  23. Nat Cell Biol. 2007 Dec;9(12):1392-400 - PubMed
  24. J Biol Chem. 2003 Dec 19;278(51):51599-605 - PubMed
  25. Cancer Res. 2008 Sep 1;68(17):6877-83 - PubMed
  26. Nat Rev Cancer. 2006 May;6(5):392-401 - PubMed
  27. J Cell Sci. 2006 Nov 1;119(Pt 21):4541-53 - PubMed
  28. Pediatr Res. 2009 Jan;65(1):27-32 - PubMed
  29. Front Immunol. 2011 Oct 12;2:50 - PubMed
  30. Dev Cell. 2006 Sep;11(3):349-61 - PubMed
  31. Acta Neuropathol. 2006 May;111(5):483-8 - PubMed
  32. J Immunol. 2009 May 1;182(9):5789-99 - PubMed
  33. J Immunol. 2007 Dec 1;179(11):7535-43 - PubMed
  34. Am J Pathol. 2011 Apr;178(4):1662-75 - PubMed
  35. Thromb Res. 2012 Apr;129 Suppl 1:S30-7 - PubMed
  36. Annu Rev Physiol. 2003;65:669-95 - PubMed
  37. Biochem J. 1999 Jul 15;341 ( Pt 2):277-84 - PubMed
  38. Immunity. 2011 Dec 23;35(6):986-96 - PubMed
  39. Immunity. 2006 Dec;25(6):989-1001 - PubMed
  40. Cell Growth Differ. 1990 Nov;1(11):511-8 - PubMed
  41. Dev Dyn. 2008 Mar;237(3):847-57 - PubMed
  42. Rom J Morphol Embryol. 2010;51(2):229-34 - PubMed
  43. Br J Cancer. 2007 Jan 15;96(1):1-5 - PubMed
  44. J Thromb Haemost. 2012 Mar;10(3):484-6 - PubMed
  45. Cell Physiol Biochem. 2010;25(1):103-12 - PubMed
  46. Am J Pathol. 2005 Mar;166(3):913-21 - PubMed
  47. J Cell Sci. 1999 Dec;112 ( Pt 24):4601-13 - PubMed
  48. J Biol Chem. 2010 Aug 6;285(32):24494-507 - PubMed
  49. Int J Cancer. 2008 Sep 1;123(5):1053-9 - PubMed
  50. Glycoconj J. 2004;19(7-9):517-26 - PubMed
  51. Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L543-51 - PubMed
  52. Am J Respir Cell Mol Biol. 1996 Jun;14(6):577-85 - PubMed
  53. Am J Pathol. 2001 Sep;159(3):787-93 - PubMed
  54. Nat Rev Cancer. 2012 Feb 24;12(3):210-9 - PubMed
  55. J Anat. 2012 May;220(5):435-46 - PubMed
  56. Dev Dyn. 2002 Nov;225(3):351-7 - PubMed
  57. Exp Cell Res. 2009 Jun 10;315(10):1715-23 - PubMed
  58. Curr Opin Cell Biol. 2007 Oct;19(5):572-7 - PubMed
  59. Blood. 2010 Jul 29;116(4):661-70 - PubMed
  60. Nat Rev Cancer. 2003 Nov;3(11):859-68 - PubMed
  61. Nat Rev Mol Cell Biol. 2010 Apr;11(4):276-87 - PubMed
  62. Nat Rev Cancer. 2002 Jun;2(6):442-54 - PubMed
  63. FEBS Lett. 2010 Sep 24;584(18):3955-61 - PubMed
  64. Dev Dyn. 2009 Jan;238(1):183-93 - PubMed
  65. Am J Pathol. 2011 Aug;179(2):1041-9 - PubMed
  66. J Immunol. 1988 Mar 1;140(5):1581-7 - PubMed
  67. J Immunol. 2009 Apr 1;182(7):4150-7 - PubMed
  68. Oncology. 2009;77(1):53-62 - PubMed
  69. Bone. 1996 Feb;18(2):125-32 - PubMed
  70. Gene. 2006 Aug 15;378:52-7 - PubMed
  71. Immunity. 2012 Aug 24;37(2):276-89 - PubMed
  72. J Histochem Cytochem. 1992 May;40(5):651-64 - PubMed
  73. Virchows Arch. 2006 Apr;448(4):493-9 - PubMed
  74. Cancer Cell. 2006 Apr;9(4):261-72 - PubMed
  75. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12694-9 - PubMed
  76. Proc Natl Acad Sci U S A. 1990 May;87(10):3982-6 - PubMed
  77. Biochem Biophys Res Commun. 2012 May 25;422(1):194-9 - PubMed
  78. Cancer Metastasis Rev. 2006 Dec;25(4):677-94 - PubMed
  79. Nat Immunol. 2012 Apr 01;13(5):499-510 - PubMed
  80. Am J Pathol. 1997 Oct;151(4):1141-52 - PubMed
  81. Pathol Int. 2005 Feb;55(2):83-6 - PubMed
  82. Eur J Immunol. 2000 Feb;30(2):697-704 - PubMed
  83. Blood. 2008 Sep 1;112(5):1730-9 - PubMed
  84. Dev Biol. 2003 Apr 1;256(1):61-72 - PubMed
  85. Tumour Biol. 2005 Jul-Aug;26(4):195-200 - PubMed
  86. Nat Rev Immunol. 2010 Dec;10(12):813-25 - PubMed
  87. Dev Biol. 1995 Jan;167(1):294-306 - PubMed
  88. Int J Biochem Cell Biol. 2011 Jun;43(6):886-96 - PubMed
  89. J Clin Invest. 2008 Nov;118(11):3725-37 - PubMed
  90. J Exp Med. 1992 Nov 1;176(5):1477-82 - PubMed
  91. Arthritis Res Ther. 2011 Mar 07;13(2):R40 - PubMed
  92. J Dermatol Sci. 2012 Feb;65(2):134-40 - PubMed
  93. Blood. 2010 May 13;115(19):3997-4005 - PubMed

Publication Types

Grant support